Related Experiment Video

Updated: Jun 2, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

Mean platelet volume as a fibrosis marker in patients with chronic hepatitis B

Fuat Ekiz1, Osman Yüksel, Erdem Koçak

  • 1Dışkapı Yıldırım Beyazıt Educational and Research Hospital, Department of Gastroenterology, Ankara, Turkey. dr_ekiz@yahoo.com

Journal of Clinical Laboratory Analysis
|May 14, 2011
PubMed

Insights

Mean platelet volume (MPV) is elevated in patients with chronic hepatitis B (CHB) and correlates with advanced liver fibrosis. While MPV may aid fibrosis assessment in CHB, it is not a standalone diagnostic tool.

Area of Science:

  • Hepatology
  • Hematology
  • Diagnostic Markers

Background:

  • Noninvasive tests are crucial for diagnosing liver fibrosis.
  • Assessing liver fibrosis score (LFS) in chronic hepatitis B (CHB) is essential for patient management.
  • The correlation between mean platelet volume (MPV) and liver fibrosis stage in CHB requires further investigation.

Purpose of the Study:

  • To investigate the relationship between MPV and the stage of liver fibrosis in patients with CHB.
  • To determine if MPV can serve as a noninvasive marker for advanced fibrosis in CHB patients.

Main Methods:

  • Retrospective study of 59 CHB patients and 25 healthy controls.
  • Data collected included HBV-DNA, liver function tests, and MPV.
  • Patients were categorized into groups with and without advanced fibrosis (F3-F4).

Main Results:

  • MPV levels were significantly higher in CHB patients compared to controls (P<0.001).
  • MPV was significantly elevated in patients with advanced fibrosis (Group 2) versus those without (Group 1) (P=0.009).
  • MPV was independently associated with advanced fibrosis in multivariable analysis (P=0.031).

Conclusions:

  • MPV may be a useful indicator for assessing liver fibrosis in CHB patients.
  • MPV's nonspecificity necessitates its use in conjunction with other diagnostic tools.
  • Further research is needed to validate MPV's role in fibrosis staging.
Abstract

More Related Videos

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry04:32

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...